Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 4Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Everolimus 16Octreotide 6pembrolizumab 5lanreotide 5Sunitinib 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3lenvatinib 3arginyllysine 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2pasireotide 2lutetium Lu 177 dotatate 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroendocrine Tumors × MK 2206 × Clear all
NCT01169649 2016-02-18

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
11 enrolled 6 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡